K

Regeneron Ventures logo

Regeneron Ventures

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Series A

Truveta logo
Truveta

Genomic database • Electronic health records

Regeneron logo
Illumina logo

Truveta is a healthcare data company that uses de-identified electronic health records and genomic data to advance medical research and improve healthcare delivery.

Series C
$320M
01/16/2025
Article
Normunity logo
Normunity

Biotechnology • T cell engager

Samsara BioCapital logo
Regeneron Ventures logo
Pfizer Ventures logo
Osage Venture Partners logo

Normunity is a biotechnology company developing anti-cancer therapies that target novel tumor-specific mechanisms to engage T cells and suppress immune evasion in solid tumors.

Series B
$75M
01/13/2025
Article
Tune Therapeutics logo
Tune Therapeutics

Epigenome editing • Gene repression

Tune Therapeutics is a company specializing in epigenome editing to develop therapies for chronic diseases, including a clinical-stage drug for chronic Hepatitis B.

Series B
$175M
01/13/2025
Article
Tasca Therapeutics logo
Tasca Therapeutics

Biotechnology • Drug Discovery

Cure Ventures logo
Regeneron Ventures logo
Invus Group logo

Tasca Therapeutics is a biotechnology company focused on developing small molecule inhibitors for oncology using a unique drug discovery platform.

Series A
$52M
12/10/2024
Article
City Therapeutics logo
City Therapeutics

Biopharmaceutical • RNAi

ARCH Venture Partners logo
Regeneron Ventures logo
Rock Springs Capital logo
Slate Path Capital logo

City Therapeutics is a biopharmaceutical company focused on developing RNA interference-based medicines using engineered small interfering RNAs to target a broad range of diseases.

Series A
$135M
10/08/2024
Article
ArsenalBio logo
ArsenalBio

Programmable cell therapy • Clinical development

Westlake Village BioPartners logo
T. Rowe Price Associates logo
SoftBank logo
Rock Springs Capital logo

Arsenal Biosciences, Inc. is a clinical-stage company developing programmable T cell therapies for solid tumor cancers using a computationally driven approach.

Series C
$325M
09/04/2024
Article